- #Actimmune interferon gamma 1b copay assistance professional#
- #Actimmune interferon gamma 1b copay assistance free#
Use a different body area each time you give yourself a shot. You will be shown the body areas where this shot can be given. If you have any questions about any of this, check with your doctor. Read this sheet carefully and make sure you understand: This medicine is given as a shot under your skin, usually in the right and left upper arms, or thighs.Įach package of interferon gamma-1b contains a patient instruction sheet. The effects may be increased because of slower removal of the medicine. Nervous system problems, or history of or Make sure you tell your doctor if you have any other medical problems, especially: The presence of other medical problems may affect the use of this medicine.
#Actimmune interferon gamma 1b copay assistance professional#
Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Other InteractionsĬertain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter ) medicine. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Drug InteractionsĪlthough certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding. There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. However, elderly patients are more likely to have age-related kidney, liver, or heart problems, which may require caution and an adjustment in the dose for patients receiving Actimmune®. GeriatricĪppropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of Actimmune® in the elderly. However, safety and efficacy have not been established in children to treat CGD younger than 1 year of age, and in newborns with SMO. "Obtaining worldwide rights for interferon gamma-1b solidifies our continued investment in the medicine, and pending the outcome of clinical studies investigating it in Friedreich's ataxia and advanced solid tumors, such as kidney and bladder cancer, strengthens our ability to expand its potential global use," noted Timothy Walbert, chairman, president and chief executive of Horizon.Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of Actimmune® to treat CGD in children 1 year of age and older, and to treat SMO in children 1 month and older. The therapy is currently not approved for this indication top line results from a Phase III trials assessing its safety and efficacy in this patient population are expected by the end of the year. In a separate agreement, Horizon has also snapped up US, European and Canadian intellectual property rights for interferon gamma-1b for the treatment of Friedreich's ataxia from an undisclosed their party. The transaction is expected to close by year-end 2016, subject to the satisfaction of closing conditions.
Under the terms of the deal, Horizon has paid Boehringer 5 million euros upon signing and will pay 20 million euros upon closing for the rights for interferon gamma-1b in all territories outside of the US, Canada and Japan.
#Actimmune interferon gamma 1b copay assistance free#
In the US the drug is marketed under the trade name Actimmune, and is approved for reducing the frequency and severity of serious infections linked to chronic granulomatous disease and for extending progression free survival in patients with severe, malignant osteopetrosis. The move will leave the firm with global rights to the drug - a biologically manufactured protein similar to one the body makes naturally to help prevent infection - as it already owns those for the rest of the world. Dublin-Ireland based biopharma Horizon Pharma has bagged rights to Boehringer Ingelheim's interferon gamma-1b in an around 30 countries primarily in Europe and the Middle East for 25 million euros.
0 kommentar(er)
